857 related articles for article (PubMed ID: 34579759)
21. Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies.
Cilibrasi C; Papanastasopoulos P; Samuels M; Giamas G
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769447
[TBL] [Abstract][Full Text] [Related]
22. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
23. Current Advances in Immunotherapy for Glioblastoma.
Mende AL; Schulte JD; Okada H; Clarke JL
Curr Oncol Rep; 2021 Jan; 23(2):21. PubMed ID: 33496872
[TBL] [Abstract][Full Text] [Related]
24. Challenges and perspectives for immunotherapy in oesophageal cancer: A look to the future (Review).
Lampis A; Ratti M; Ghidini M; Mirchev MB; Okuducu AF; Valeri N; Hahne JC
Int J Mol Med; 2021 Jun; 47(6):. PubMed ID: 33846775
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy a New Hope for Cancer Treatment: A Review.
Nouri Rouzbahani F; Shirkhoda M; Memari F; Dana H; Mahmoodi Chalbatani G; Mahmoodzadeh H; Samarghandi N; Gharagozlou E; Mohammadi Hadloo MH; Maleki AR; Sadeghian E; Nia E; Nia N; Hadjilooei F; Rezaeian O; Meghdadi S; Miri S; Jafari F; Rayzan E; Marmari V
Pak J Biol Sci; 2018; 21(3):135-150. PubMed ID: 30187723
[TBL] [Abstract][Full Text] [Related]
26. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic viruses as engineering platforms for combination immunotherapy.
Twumasi-Boateng K; Pettigrew JL; Kwok YYE; Bell JC; Nelson BH
Nat Rev Cancer; 2018 Jul; 18(7):419-432. PubMed ID: 29695749
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations.
Butterfield LH; Najjar YG
Nat Rev Immunol; 2024 Jun; 24(6):399-416. PubMed ID: 38057451
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy for the Treatment of Urothelial Carcinoma.
Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
[TBL] [Abstract][Full Text] [Related]
30. The viral approach to breast cancer immunotherapy.
Arab A; Behravan N; Razazn A; Barati N; Mosaffa F; Nicastro J; Slavcev R; Behravan J
J Cell Physiol; 2019 Feb; 234(2):1257-1267. PubMed ID: 30146692
[TBL] [Abstract][Full Text] [Related]
31. Current Immunotherapies for Glioblastoma Multiforme.
Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
Front Immunol; 2020; 11():603911. PubMed ID: 33767690
[TBL] [Abstract][Full Text] [Related]
32. The expanding role of immunotherapy.
Martin-Liberal J; Ochoa de Olza M; Hierro C; Gros A; Rodon J; Tabernero J
Cancer Treat Rev; 2017 Mar; 54():74-86. PubMed ID: 28231560
[TBL] [Abstract][Full Text] [Related]
33. The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment.
Uche IK; Kousoulas KG; Rider PJF
Viruses; 2021 Jun; 13(7):. PubMed ID: 34206677
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
[TBL] [Abstract][Full Text] [Related]
35. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
Rajani KR; Vile RG
Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
[TBL] [Abstract][Full Text] [Related]
36. Immune checkpoint modulation: rational design of combination strategies.
Zamarin D; Postow MA
Pharmacol Ther; 2015 Jun; 150():23-32. PubMed ID: 25583297
[TBL] [Abstract][Full Text] [Related]
37. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.
Ghidini M; Fusco N; Salati M; Khakoo S; Tomasello G; Petrelli F; Trapani D; Petrillo A
Curr Drug Targets; 2021; 22(9):1021-1033. PubMed ID: 33563194
[TBL] [Abstract][Full Text] [Related]
38. Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus.
Farrera-Sal M; Moya-Borrego L; Bazan-Peregrino M; Alemany R
Clin Cancer Res; 2021 Jun; 27(11):2979-2988. PubMed ID: 33526422
[TBL] [Abstract][Full Text] [Related]
39. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
Cavalcante L; Chowdhary A; Sosman JA; Chandra S
Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies.
Guo Y; Gao F; Ahmed A; Rafiq M; Yu B; Cong H; Shen Y
J Mater Chem B; 2023 Sep; 11(36):8586-8604. PubMed ID: 37614168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
